UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO‐K1 cells expressing human angiotensin II AT1 receptors

British journal of pharmacology, 1999-02, Vol.126 (4), p.1057-1065

1999

Volltextzugriff (PDF)

P278 Radiation exposure in patients with inflammatory bowel disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i645-i645

2024

Volltextzugriff (PDF)

P159 Development of a core set of quality of care measurements for patients with inflammatory bowel disease in Belgium

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i318-i319

2023

Volltextzugriff (PDF)

POS0157 IMPLEMENTATION OF A VACCINATION TOOL IN THE ELECTRONIC PATIENT HEALTH RECORD COINCIDES WITH A SIGNIFICANT INCREASE IN VACCINATION COVERAGE

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.307-307

2022

Volltextzugriff (PDF)

PCR107 General and Scalable Versus Disease-Specific and Targeted: To What Extent Should We Measure Outcomes From These Two Areas?

Value in health, 2022-12, Vol.25 (12), p.S411-S411

2022

Volltextzugriff (PDF)

P335 Development and validation of a Belgian set of quality indicators for inflammatory bowel diseases

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i726-i727

2024

Volltextzugriff (PDF)

P280 Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studies

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S313-S314

2021

Volltextzugriff (PDF)

P115 Implementation of a vaccination tool in the electronic patient health record significantly increases vaccination coverage

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i206-i207

2022

Volltextzugriff (PDF)

A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process

Journal of Crohn's and colitis, 2024-10, Vol.18 (10), p.1583

2024

Volltextzugriff (PDF)

P484 Remote monitoring allows an individualized approach and showed excellent usability at the infusion unit

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S472-S473

2021

Volltextzugriff (PDF)

P347 Practical recommendations for the collection of the patient-reported outcomes included in the Health Outcomes Observatory (H2O) core data set for patients with inflammatory bowel disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i484-i485

2023

Volltextzugriff (PDF)

Insurmountable angiotensin AT1 receptor antagonists : the role of tight antagonist binding

European journal of pharmacology, 1999-05, Vol.372 (2), p.199-206

1999

Volltextzugriff (PDF)

Chronic corticosterone manipulations in mice affect brain cell proliferation rates, but only partly affect BDNF protein levels

Neuroscience letters, 2006-03, Vol.396 (1), p.12-16

2006

Volltextzugriff (PDF)

P219 Disease-specific avoidance is a predictor for fatigue in inflammatory bowel disease patients

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S250-S252

2020

Volltextzugriff (PDF)

A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists

Biochemical pharmacology, 2001-02, Vol.61 (3), p.277-284

2001

Volltextzugriff (PDF)

Angiotensin II type 1 receptor antagonists: Why do some of them produce insurmountable inhibition?

Biochemical pharmacology, 2000-12, Vol.60 (11), p.1557-1563

2000

Volltextzugriff (PDF)

Practical recommendations for the collection of the patient-reported outcomes included in the Health Outcomes Observatory (H2O) core data set for patients with inflammatory bowel disease

JOURNAL OF CROHNS & COLITIS, 2023, Vol.17, p.484

2023

Volltextzugriff (PDF)

Molecular characterization of the high-affinity [3H]neuropeptide Y-binding component from the venom of Conus anemone

Fundamental & clinical pharmacology, 2003-08, Vol.17 (4), p.457-462

2003

Volltextzugriff (PDF)

Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors

Fundamental & clinical pharmacology, 2000-11, Vol.14 (6), p.577-585

2000

Volltextzugriff (PDF)

Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors

Biochemical pharmacology, 2000-04, Vol.59 (8), p.927-935

2000

Volltextzugriff (PDF)

Gene expression profiles highlight adaptive brain mechanisms in corticotropin releasing factor overexpressing mice

Brain research. Molecular brain research., 2004-10, Vol.129 (1), p.135-150

2004

Volltextzugriff (PDF)

Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors

Pharmaceutical research, 2000-12, Vol.17 (12), p.1482-1488

2000

Volltextzugriff (PDF)

The effects of candesartan on human AT1 receptor-expressing Chinese hamster ovary cells

Journal of the American Society of Nephrology, 1999, Vol.10, p.15-17

1999

Volltextzugriff (PDF)

Distinction between surmountable and insurmountable selective AT 1 receptor antagonists by use of CHO‐K1 cells expressing human angiotensin II AT 1 receptors

British journal of pharmacology, 2009-01, Vol.126 (4), p.1057-1065

2009

Volltextzugriff (PDF)

Binding characteristics of [3H]-irbesartan to human recombinant angiotensin type 1 receptors

Journal of the renin-angiotensin-aldosterone system, 2000-06, Vol.1 (2), p.159-165

2000

Volltextzugriff (PDF)

1 – 25 von 275

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(190)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Französisch
(149)
Englisch
(133)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO‐K1 cells expressing human angiotensin II AT1 receptors

P278 Radiation exposure in patients with inflammatory bowel disease

P159 Development of a core set of quality of care measurements for patients with inflammatory bowel disease in Belgium

POS0157 IMPLEMENTATION OF A VACCINATION TOOL IN THE ELECTRONIC PATIENT HEALTH RECORD COINCIDES WITH A SIGNIFICANT INCREASE IN VACCINATION COVERAGE

PCR107 General and Scalable Versus Disease-Specific and Targeted: To What Extent Should We Measure Outcomes From These Two Areas?

P335 Development and validation of a Belgian set of quality indicators for inflammatory bowel diseases

P280 Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studies

P115 Implementation of a vaccination tool in the electronic patient health record significantly increases vaccination coverage

A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process

P484 Remote monitoring allows an individualized approach and showed excellent usability at the infusion unit

P347 Practical recommendations for the collection of the patient-reported outcomes included in the Health Outcomes Observatory (H2O) core data set for patients with inflammatory bowel disease

Insurmountable angiotensin AT1 receptor antagonists : the role of tight antagonist binding

Chronic corticosterone manipulations in mice affect brain cell proliferation rates, but only partly affect BDNF protein levels

P219 Disease-specific avoidance is a predictor for fatigue in inflammatory bowel disease patients

A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists

Angiotensin II type 1 receptor antagonists: Why do some of them produce insurmountable inhibition?

Practical recommendations for the collection of the patient-reported outcomes included in the Health Outcomes Observatory (H2O) core data set for patients with inflammatory bowel disease

Molecular characterization of the high-affinity [3H]neuropeptide Y-binding component from the venom of Conus anemone

Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors

Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors

Gene expression profiles highlight adaptive brain mechanisms in corticotropin releasing factor overexpressing mice

Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors

The effects of candesartan on human AT1 receptor-expressing Chinese hamster ovary cells

Distinction between surmountable and insurmountable selective AT 1 receptor antagonists by use of CHO‐K1 cells expressing human angiotensin II AT 1 receptors

Binding characteristics of [3H]-irbesartan to human recombinant angiotensin type 1 receptors

Suchergebnisse filtern